About Bayer Essure (NASDAQ:CPTS)
Conceptus, Inc. designs, develops, markets and promotes solutions in women's healthcare. The Company's flagship product is the Essure permanent birth control procedure, which is the non-surgical permanent birth control system. The Essure delivers a soft and flexible insert into a woman's fallopian tubes, causing a benign tissue in-growth, which blocks the fallopian tubes. Successfully placed Essure inserts and the subsequent tissue growth around, and through the inserts prohibits the egg from traveling through the fallopian tube, preventing conception. In October 2011, the Company acquired from its Dutch distributor certain assets and all distribution rights of the Essure device. In October 2011, it purchased certain assets of Sigma Medical and established a wholly owned subsidiary in the Netherlands, Conceptus B.V. (BV). During the year ended December 31, 2011, approximately 600,000 women worldwide have undergone the Essure procedure.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNASDAQ:CPTS
CUSIP20601610
Phone+1-302-6365400
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Bayer Essure (NASDAQ:CPTS) Frequently Asked Questions
What is Bayer Essure's stock symbol?
Bayer Essure trades on the NASDAQ under the ticker symbol "CPTS."
Has Bayer Essure been receiving favorable news coverage?
News articles about CPTS stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bayer Essure earned a media sentiment score of 0.05 on Accern's scale. They also assigned media coverage about the healthcare company an impact score of 47.60 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Bayer Essure?
Shares of CPTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Bayer Essure?
Bayer Essure's mailing address is 100 Bayer Rd, PITTSBURGH, PA 15205-9707, United States. The healthcare company can be reached via phone at +1-302-6365400.
MarketBeat Community Rating for Bayer Essure (CPTS)
MarketBeat's community ratings are surveys of what our community members think about Bayer Essure and other stocks. Vote "Outperform" if you believe CPTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bayer Essure (NASDAQ:CPTS) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/25/2016 forward)
Bayer Essure (NASDAQ:CPTS) Earnings History and Estimates Chart
Bayer Essure (NASDAQ CPTS) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/30/2013 | Q1 2013 | | $0.05 | $31.94 million | $34.10 million | View | N/A |  |
| 2/5/2013 | Q4 2012 | $0.11 | $0.17 | $40.20 million | $40.73 million | View | N/A | |
| 10/23/2012 | | $0.06 | $0.07 | | | View | N/A | |
| 4/26/2012 | | ($0.13) | ($0.09) | | | View | N/A | |
| 2/23/2012 | | $0.02 | ($0.08) | | | View | N/A | |
| 10/25/2011 | | $0.02 | ($0.09) | | | View | N/A | |
| 8/4/2011 | | | $0.01 | | | View | N/A | |
| 5/10/2011 | | ($0.05) | ($0.09) | | | View | N/A | |
| 2/24/2011 | | $0.18 | $2.66 | | | View | N/A | |
| 10/28/2010 | Q3 2010 | $0.06 | $0.10 | | | View | N/A | |
| 8/5/2010 | Q2 2010 | | ($0.01) | | | View | N/A | |
| 4/20/2010 | Q1 2010 | ($0.08) | ($0.08) | | | View | N/A | |
| 2/23/2010 | Q4 2009 | $0.21 | $0.21 | | | View | N/A | |
| 10/21/2009 | Q3 2009 | $0.09 | $0.24 | | | View | N/A | |
| 7/22/2009 | Q2 2009 | ($0.05) | ($0.02) | | | View | N/A | |
| 4/21/2009 | Q1 2009 | ($0.15) | ($0.14) | | | View | N/A | |
| 2/17/2009 | Q4 2008 | $0.18 | $0.17 | | | View | N/A | |
| 10/29/2008 | Q3 2008 | $0.07 | $0.10 | | | View | N/A | |
| 7/23/2008 | Q2 2008 | ($0.04) | ($0.05) | | | View | N/A | |
| 5/6/2008 | Q1 2008 | ($0.17) | ($0.21) | | | View | N/A | |
| 2/19/2008 | Q4 2007 | ($0.08) | ($0.09) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Bayer Essure (NASDAQ:CPTS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Bayer Essure (NASDAQ CPTS) Insider Trading and Institutional Ownership History
Bayer Essure (NASDAQ CPTS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2013 | Peter Wilson | Director | Sell | 30,000 | $25.00 | $750,000.00 | | |
(Data available from 1/1/2013 forward)
Bayer Essure (NASDAQ CPTS) News Headlines
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Bayer Essure (NASDAQ:CPTS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bayer Essure (NASDAQ:CPTS) Income Statement, Balance Sheet and Cash Flow Statement
Bayer Essure (NASDAQ CPTS) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
